Epidemiological features of hepatitis B in the Russian Arctic

Abstract

BACKGROUND: Hepatitis B is an urgent medical and social problem in Russia.

AIM: To determine the epidemiological features of the hepatitis B in the Russian Arctic.

MATERIALS AND METHODS: We carried out a retrospective analysis of the incidence of hepatitis B (acute and chronic forms) in 9 Russian Arctic regions, 3 subarctic regions (Khanty-Mansiysk Autonomous Okrug, Magadan Region, Kamchatka Territory) and Russian Federation in 1999–2019. We also studied the prevalence of chronic hepatitis B and vaccination data against hepatitis B in these territories.

RESULTS: From 1999 to 2019 the incidence of acute hepatitis B in three subarctic regions decreased 166 times (from 66.5 to 0.4 per 100 thousand population), in the Arctic zone of 74.5 times (from 29.8 to 0.4 per 100 thousand population) and 73 times in Russia (from 43.8 to 0.6). The incidence of chronic hepatitis forms in the same period in the Arctic zone decreased by 8.6 times (from 140.1 to 16.3), 5.8 times in the subarctic regions (from 116.6 to 20.0) and 5.7 times in Russia (from 96.3 to 16.8). In 2018, the results of the prevalence of chronic hepatitis B in the Arctic zone (697.3) was higher than in Russia by 98% (352.1) and higher in the subarctic regions by 67% (588.6). Timely coverage of hepatitis vaccination in children aged 12 months in the Russian Federation, the Arctic zone and the subarctic regions is maintained at a high level (more than 90%) from 2004 in 2019. Coverage of children by vaccination to 17 years inclusive and adults up to 35 years on these territories also exceeded 90%.

CONCLUSIONS: Vaccination against hepatitis B in the Russian Federation led to a significant decrease in the incidence of this infection in the Russian Arctic. High prevalence of infection indicates the need to continue the program of mass vaccination and the timely introduction of the first dose of vaccine newborns. To reduce the risk of cirrhosis and liver cancer, it is necessary to increase the availability of diagnosis of the disease and its possible outcomes in the Arctic regions and timely provision of antiviral treatment of all patients.

Keywords

hepatitis / Arctic / epidemiology / incidence / prevalence / vaccination

References

[1] Lukin YF. Status, composition, population of the Russian Arctic. Arctic and North. 2014;(15):57–94. (In Russ).

[2] Лукин Ю.Ф. Статус, состав, население Российской Арктики // Арктика и Север. 2014. № 15. C. 57–94.

[3] Fauzer VV, Smirnov AV. The world's arctic: natural resources, population distribution, economics. Arctic: Ecology and Economy. 2018;3(31):6–22. doi: 10.25283/2223-4594-2018-3-6-22

[4] Fauzer V.V., Smirnov A.V. The World's Arctic natural resources, population distribution, economics // Arctic: Ecology and Economy. 2018. Vol. 31, № 3. P. 6–22. doi: 10.25283/2223-4594-2018-3-6-22

[5] Bruce M, Zulz T, Koch A. Surveillance of infectious diseases in the Arctic. Public Health. 2016;137:5–12. doi: 10.1016/j.puhe.2016.06.014

[6] Bruce M., Zulz T., Koch A. Surveillance of infectious diseases in the Arctic // Public Health. 2016. Vol. 137. P. 5–12. doi: 10.1016/j.puhe.2016.06.014

[7] Petrova PG, Borisova NV, Platonov FA, Turkebaeva LK. The role of field research in the study of public health in the Arctic. Bulletin of the Northeastern Federal University named after M.K. Ammosov. 2017;(2):4. (In Russ).

[8] Петрова П.Г., Борисова Н.В., Платонов Ф.А., Туркебаева Л.К. Роль экспедиционных исследований в изучении здоровья населения Арктики // Вестник Северо-Восточного федерального университета имени М.К. Аммосова. 2017. № 2. C. 4.

[9] Volova LU, Rodina EV. HIV epidemic situation among Small Indigenous Populations of Northeast Russia. J Infectology. 2014; 6(2):76–82. (In Russ).

[10] Волова Л.Ю., Родина Е.В. Эпидемиологическая ситуация по ВИЧ-инфекции среди представителей коренных малочисленных народов Севера // Журнал инфектологии. 2014. Т. 6, № 2. С. 76–82.

[11] Toropushina EE. Estimation of the social in frastructure development in the North and the Arctic of Russia. EKO. 2016; (6):99–108. (In Russ).

[12] Торопушина Е.Е. Оценка уровня развития социальной инфраструктуры в регионах Севера и Арктики России // ЭКО. 2016. № 6. C. 99–108.

[13] Zalyalov BA, Pimenov NN, Komarova SV, et al. Epidemiological features of hepatitis B and C in the Arctic Region. Epidemiology and Infectious Diseases. Current Items. 2019;9(1):81–92. (In Russ). doi: 10.18565/epidem.2019.1.81-92

[14] Залялов Б.А., Пименов Н.Н., Комарова С.В., и др. Эпидемиологические особенности гепатитов В и С в Арктике // Эпидемиология и инфекционные болезни. Актуальные вопросы. 2019. Т. 9, № 1. C. 81–92. doi: 10.18565/epidem.2019.1.81-92

[15] Petrova DP, Mindlina AY. Comparative analysis of the morbidity of respiratory infections in the Arctic Zone and other Territories of Russia. Epidemiology and Vaccinal Prevention. 2020;19(4): 48–56. (In Russ). doi: 10.31631/2073-3046-2020-19-4-48-56

[16] Петрова Д.П., Миндлина А.Я. Сравнительный анализ заболеваемости респираторными инфекциями на территориях Арктической зоны и других территориях России // Эпидемиология и вакцинопрофилактика. 2020. Т. 19, № 4. C. 48–56. doi: 10.31631/2073-3046-2020-19-4-48-56

[17] Osiowy C, Simons BC, Rempel JD. Distribution of viral hepatitis in indigenous populations of North America and the circumpolar Arctic. Antivir Ther. 2013;18(3 Pt B):467–473. doi: 10.3851/IMP2597

[18] Osiowy C., Simons B.C., Rempel J.D. Distribution of viral hepatitis in indigenous populations of North America and the circumpolar Arctic // Antiviral Therapy. 2013. Vol. 18, № 3 (Pt B). P. 467–473. doi: 10.3851/IMP2597

[19] Sleptsova SS. Parenteral viral hepatitis and their outcomes in the Republic of Sakha (Yakutia). Moscow: Chekhovskii Pechatnyi Dvor; 2017. 216 р. (In Russ).

[20] Слепцова С.С. Парентеральные вирусные гепатиты и их исходы в республике Саха (Якутия). Москва: Чеховский Печатный Двор, 2017. 216 с.

[21] Semenov SI, Savvin RG, Krivoshapkin VG, et al. Epidemiological characteristics of hepatitis with parenteral transmission mechanism of pathogens in Yakutia. Far Eastern Journal of Infectious Pathology. 2004;(5):20–23. (In Russ).

[22] Семенов С.И., Саввин Р.Г., Кривошапкин В.Г., и др. Эпидемиологическая характеристика гепатитов с парентеральным механизмом передачи возбудителей в Якутии // Дальневосточный журнал инфекционной патологии. 2004. № 5. C. 20–23.

[23] Ohba K, Mizokami M, Kato T, et al. Seroprevalence of hepatitis B virus, hepatitis C virus and GB virus-C infections in Siberia. Epidemiol Infect. 1999;122(1):139–143. doi: 10.1017/s0950268898001940

[24] Ohba K., Mizokami M., Kato T., et al. Seroprevalence of hepatitis B virus, hepatitis C virus and GB virus-C infections in Siberia // Epidemiol Infect. 1999. Vol. 122, № 1. P. 139–143. doi: 10.1017/s0950268898001940

[25] Bugaeva TT, Alexeeva MN, Ivanov PM, et al. The chronic viral hepatitis as main risk factors of hepatocellular carcinoma development in Yakutia. Siberian Medical J. 2007;22(S2):47–49. (In Russ).

[26] Бугаева Т.Т., Алексеева М.Н., Иванов П.М., и др. Хронические вирусные гепатиты как основные факторы риска развития гепатоцеллюлярной карциномы в Якутии // Сибирский медицинский журнал. 2007. Т. 22, № S2. C. 47–49.

[27] McMahon BJ, Bulkow LR, Singleton RJ, et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology. 2011;54(3):801–807. doi: 10.1002/hep.24442

[28] McMahon B.J., Bulkow L.R., Singleton R.J., et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program // Hepatology. 2011. Vol. 54, № 3. P. 801–807. doi: 10.1002/hep.24442

[29] Mereckiene J, Cotter S, Lopalco P, et al. Hepatitis B immunisation programmes in European Union, Norway and Iceland: Where we were in 2009? Vaccine. 2010;28(28):4470–4477. doi: 10.1016/j.vaccine.2010.04.037

[30] Mereckiene J., Cotter S., Lopalco P., et al. Hepatitis B immunisation programmes in European Union, Norway and Iceland: where we were in 2009? // Vaccine. 2010. Vol. 28, № 28. P. 4470–4477. doi: 10.1016/j.vaccine.2010.04.037

[31] FitzSimons D, McMahon B, Hendrickx G, et al. Burden and prevention of viral hepatitis in the Arctic region, Copenhagen, Denmark, 22–23 March, 2012. Int J Circumpolar Health. 2013;72:21163. doi: 10.3402/ijch.v72i0.21163

[32] FitzSimons D., McMahon B., Hendrickx G., et al. Burden and prevention of viral hepatitis in the Arctic region, Copenhagen, Denmark, 22–23 March 2012 // Int J Circumpolar Health. 2013. Vol. 72. P. 21163. doi: 10.3402/ijch.v72i0.21163

[33] Børresen ML, Koch A, Biggar RJ, et al. Effectiveness of the targeted hepatitis B vaccination program in Greenland. Am J Public Health. 2012;102(2):277–284. doi: 10.2105/ajph.2011.300239

[34] Børresen M.L., Koch A., Biggar R.J., et al. Effectiveness of the targeted hepatitis B vaccination program in Greenland // Am J Public Health. 2012. Vol. 102, № 2. P. 277–284. doi: 10.2105/ajph.2011.300239

[35] WHO. Weekly epidemiological bulletin. July 7, 2017, 92nd year, N 27, 2017, 92, 369–392. Hepatitis B vaccines: WHO position paper, July 2017 [Internet]. Available from: https://www.who.int/wer/2017/pp_hepb_2017_ru.pdf. Accessed: 09.06.2021.

[36] ВОЗ. Еженедельный эпидемиологический бюллетень. 7 июля 2017 года, 92-й год, № 27, 2017, 92, 369–392. Вакцины против гепатита В: документ по позиции ВОЗ, июль 2017 [интернет]. Режим доступа: https://www.who.int/wer/2017/pp_hepb_2017_ru.pdf. Дата обращения: 09.06.2021.

[37] Poynard T, Mathurin P, Lai CL, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol. 2003;38(3): 257–265. doi: 10.1016/s0168-8278(02)00413-0

[38] Poynard T., Mathurin P., Lai C.L., et al. A comparison of fibrosis progression in chronic liver diseases // J Hepatology. 2003. Vol. 38, № 3. P. 257–265. doi: 10.1016/s0168-8278(02)00413-0

[39] Hamada H, Yatsuhashi H, Yano K, et al. Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C. Cancer. 2002;95(2):331–339. doi: 10.1002/cncr.10662

[40] Hamada H., Yatsuhashi H., Yano K., et al. Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C // Cancer. 2002. Vol. 95, № 2. P. 331–339. doi: 10.1002/cncr.10662

[41] Kershengoltz BM, Chernobrovkina TV, Kolosova ON. Ethnogenetic features of alcohol resistance in the people of the North. Bulletin of the Northeastern Federal University named after M.K. Ammosov. 2012;9(1):22–28. (In Russ).

[42] Кершенгольц Б.М., Чернобровкина Т.В., Колосова О.Н. Этногенетические особенности устойчивости к алкоголю в популяциях народов Севера // Вестник Северо-Восточного федерального университета имени М.К. Аммосова. 2012. Т. 9, № 1. C. 22–28.

[43] Chulanov VP. Epidemiological and clinical significance of genetic heterogeneity of hepatitis A and B viruses [dissertation abstract]. Moscow; 2013. (In Russ). Available from: https://www.crie.ru/pdf/avtoref1(chulanov).pdf.

[44] Чуланов В.П. Эпидемиологическое и клиническое значение генетической гетерогенности вирусов гепатита А и В: Автореф. дис. … докт. мед. наук. Москва, 2013. Режим доступа: https://www.crie.ru/pdf/avtoref1(chulanov).pdf. Дата обращения: 25.08.2021.

[45] Zotova AV, Juman AA, Tsikina MN. Significance of viral load determination in hepatits B and C in relatively closed populations of ethnic minorities. The Far Eastern J Infectious Pathology. 2010;16(16):23–26. (In Russ).

[46] Зотова А.В., Жуман А.А., Цыкина М.Н. Значение определения вирусной нагрузки при гепатитах В и С в относительно замкнутых популяциях малых народов // Дальневосточный журнал инфекционной патологии. 2010. № 16. C. 23–26.

[47] Gounder PP, Bulkow LR, Snowball M, et al. Hepatocellular carcinoma risk in Alaska native children and young adults with hepatitis B virus: retrospective cohort analysis. J Pediatr. 2016;178:206–213. doi: 10.1016/j.jpeds.2016.08.017

[48] Gounder P.P., Bulkow L.R., Snowball M., et al. Hepatocellular carcinoma risk in Alaska native children and young adults with hepatitis B virus: retrospective cohort analysis // J Pediatrics. 2016. Vol. 178. P. 206–213. doi: 10.1016/j.jpeds.2016.08.017

[49] Livingston SE, Simonetti JP, McMahon BJ, et al. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis. 2007;195(1):5–11. doi: 10.1086/509894

[50] Livingston S.E., Simonetti J.P., McMahon B.J., et al. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F // Journal of Infectious Diseases. 2007. Vol. 195, № 1. P. 5–11. doi: 10.1086/509894

[51] McMahon BJ, Nolen S, Snowball M, et al. Hepatitis B Virus (HBV) genotype: a significant risk factor in determining which patients with chronic HBV infection should undergo surveillance for hepatocellular carcinoma: the hepatitis B Alaska (HEP-B-AK) study. Hepatology. 2021. doi: 10.1002/hep.32065

[52] McMahon B.J., Nolen S., Snowball M., et al. Hepatitis B Virus (HBV) genotype: a significant risk factor in determining which patients with chronic HBV infection should undergo surveillance for hepatocellular carcinoma: the hepatitis B Alaska (HEP-B-AK) study // Hepatology. 2021. doi: 10.1002/hep.32065

RIGHTS & PERMISSIONS

Eco-vector